Abeona Therapeutics (ABEO) Capital Expenditures (2011 - 2026)

Abeona Therapeutics' Capital Expenditures history runs 15 years deep, the most recent figure standing at $935000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 2497.44% year-over-year to $935000.0; the TTM figure through Mar 2026 stood at $1.7 million (up 275.56% YoY), while the FY2025 annual figure was $685000.0, up 478.45% from the prior year.
• Capital Expenditures for Q1 2026 stood at $935000.0, up from -$6.1 million in the prior quarter.
• The five-year high for Capital Expenditures was $5.5 million in Q3 2025, with the low at -$6.1 million in Q4 2025.
• The 5-year median for Capital Expenditures is $120500.0 (2022), against an average of $112687.5.
• Peak annual rise in Capital Expenditures reached 7800.0% in 2024, while the deepest fall reached 1564.49% in 2024.
• Abeona Therapeutics' Capital Expenditures stood at $278000.0 in 2022, then slumped by 50.36% to $138000.0 in 2023, then tumbled by 1564.49% to -$2.0 million in 2024, then slumped by 203.66% to -$6.1 million in 2025, then surged by 115.24% to $935000.0 in 2026.
• Business Quant data shows ABEO's Capital Expenditures at $935000.0 in Q1 2026, -$6.1 million in Q4 2025, and $5.5 million in Q3 2025.